Khavinson · Molecules (Basel, Switzerland) 2020 · narrative review · n=?

EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.

Cited 13 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing mechanistic and preclinical literature

PubMed 33396470 · doi:10.3390/molecules26010159 · record verified 2026-08-26

What was done

This narrative review synthesized molecular and genetic evidence regarding how the tripeptide EDR (Glu-Asp-Arg) affects gene expression and protein synthesis involved in the pathogenesis of Alzheimer's disease (AD), drawing from in vitro, animal, and clinical contexts.

What was found

The abstract reports no numerical values, effect sizes, or confidence intervals. Qualitatively, it notes that EDR is thought to enter cells and bind histones or RNA, modulating the MAPK/ERK pathway, apoptotic markers (caspase-3, p53), antioxidant enzymes (SOD2, GPX1), and transcription factors. It also references prior observations of reduced dendritic spine loss in AD and Huntington's mouse neuronal models, enhanced antioxidant enzymes in rat cerebellar cultures, normalized behavioral responses in animals, and memory improvements in elderly patients.

Why it matters

It organizes the theoretical and molecular rationale for how short peptide bioregulators could target gene expression pathways involved in neurodegenerative pathology.

Limits

The work is a narrative review presenting mechanism-based reasoning without systematic review methodology, meta-analysis, or new primary data. The abstract lacks quantitative metrics and sample sizes for the cited studies, and its concluding sentence is incomplete.

Cited by